Global Vision

NYU Stern School of Business Partners with NYU Abu Dhabi to Launch One-year Full-time MBA Program in the UAE

Retrieved on: 
Dienstag, September 19, 2023
Linda, Workforce, Faculty, Learning, IESE Business School, USC Marshall School of Business, Partnership, Student, Theseus International Management Institute, Education, NYUAD, Teaching, Curriculum, NYU, Business school, Global Vision, ABU, MBA, Research, Xavier University MBA Program, Pitfalls, Professor, Tamkeen, New York University Abu Dhabi, NEC, Management, Amusement park, Business, New York University Stern School of Business

NYU President Linda G. Mills said, "The establishment of the Stern at NYUAD MBA is truly a landmark occasion. The launch of this program – NYUAD's first professional degree offering, created in collaboration with NYU's Stern School -- is an important new stage in NYU Abu Dhabi's successful development, and a major step forward in fulfilling the vision that NYU and our Abu Dhabi partners have had for this groundbreaking institution from the beginning. It is also a wonderful example of the type of cross-school collaboration that we can expect to see more of in the coming years, and I have no doubt its impact will be felt both regionally and globally."

Key Points: 
  • New York University's Stern School of Business is the only top US business school offering a full-time MBA program in the Middle East.
  • The Stern at NYU Abu Dhabi One-year Full-time MBA Program will give students the opportunity to build future careers in the MENA region, with educational modules in both Abu Dhabi and New York.
  • ABU DHABI, UAE, Sept. 19, 2023 /PRNewswire/ -- The NYU Stern School of Business (NYU Stern), one of the world's premier research and teaching institutions, and NYU Abu Dhabi (NYUAD), an exceptional liberal arts and research university, today announced the launch of the Stern at NYUAD One-year Full-time MBA Program.
  • On successful completion of the MBA program, students will graduate with a fully accredited New York University degree, jointly conferred by NYU Stern and NYU Abu Dhabi.

NYU Stern School of Business Partners with NYU Abu Dhabi to Launch One-year Full-time MBA Program in the UAE

Retrieved on: 
Dienstag, September 19, 2023
Linda, Workforce, Faculty, Learning, IESE Business School, USC Marshall School of Business, Partnership, Student, Theseus International Management Institute, Education, NYUAD, Teaching, Curriculum, NYU, Business school, Global Vision, ABU, MBA, Research, Xavier University MBA Program, Pitfalls, Professor, Tamkeen, New York University Abu Dhabi, NEC, Management, Amusement park, Business, New York University Stern School of Business

NYU President Linda G. Mills said, "The establishment of the Stern at NYUAD MBA is truly a landmark occasion. The launch of this program – NYUAD's first professional degree offering, created in collaboration with NYU's Stern School -- is an important new stage in NYU Abu Dhabi's successful development, and a major step forward in fulfilling the vision that NYU and our Abu Dhabi partners have had for this groundbreaking institution from the beginning. It is also a wonderful example of the type of cross-school collaboration that we can expect to see more of in the coming years, and I have no doubt its impact will be felt both regionally and globally."

Key Points: 
  • New York University's Stern School of Business is the only top US business school offering a full-time MBA program in the Middle East.
  • The Stern at NYU Abu Dhabi One-year Full-time MBA Program will give students the opportunity to build future careers in the MENA region, with educational modules in both Abu Dhabi and New York.
  • ABU DHABI, UAE, Sept. 19, 2023 /PRNewswire/ -- The NYU Stern School of Business (NYU Stern), one of the world's premier research and teaching institutions, and NYU Abu Dhabi (NYUAD), an exceptional liberal arts and research university, today announced the launch of the Stern at NYUAD One-year Full-time MBA Program.
  • On successful completion of the MBA program, students will graduate with a fully accredited New York University degree, jointly conferred by NYU Stern and NYU Abu Dhabi.

Oncolytics Biotech's® Chinese Development Partner Adlai Nortye Presents Interim Clinical Data Further Demonstrating the Anti-Cancer Activity of Pelareorep-Paclitaxel Combination Therapy in HR+/HER2- Metastatic Breast Cancer at the San Antonio Breast Canc

Retrieved on: 
Donnerstag, Dezember 8, 2022
ONC, Biotechnology, Travel, PIK3CA, Global Vision, PR, Poster, Paclitaxel, Patient, Partnership, Șaeș, EP4, SD, Research, PFS, Progression-free survival, Roche, Breast cancer, Neoplasm, REO, Cancer, LINK, COVID-19, Survival, Clinical trial, Lymphatic system, AB, Safety, TSX, SAN, Pulmonary toxicity, Regulation, Pancreatic cancer, Phenotype, Medical imaging, Pharmaceutical industry, Vaccine, Pelareorep, Oncolytics Biotech

SAN DIEGO and CALGARY, AB, Dec. 8, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc.'s (NASDAQ: ONCY) (TSX: ONC) Chinese partner Adlai Nortye today announced interim results from a multicenter, single-arm bridging clinical trial to evaluate the safety, tolerability, and preliminary efficacy of pelareorep-paclitaxel combination therapy in Chinese patients with advanced/metastatic HR+/HER2- breast cancer. The data were featured in a poster presented yesterday at the San Antonio Breast Cancer Symposium (SABCS), which is being held at the Henry B. González Convention Center in San Antonio, Texas through December 10, 2022.

Key Points: 
  • 's (NASDAQ: ONCY) (TSX: ONC) Chinese partner Adlai Nortye today announced interim results from a multicenter, single-arm bridging clinical trial to evaluate the safety, tolerability, and preliminary efficacy of pelareorep-paclitaxel combination therapy in Chinese patients with advanced/metastatic HR+/HER2- breast cancer.
  • One patient achieving a PR at week 8 has maintained the PR through week 48 and remains on study.
  • The studied combination has been well tolerated, with no dose-limiting toxicities or serious adverse events (SAEs) reported to date.
  • "With no SAEs reported, the data suggests the favorable safety and potent anti-cancer activity displayed by the studied combination in North American HR+/HER2- breast cancer patients extends to the Chinese population.

Oncolytics Biotech's® Chinese Development Partner Adlai Nortye Presents Interim Clinical Data Further Demonstrating the Anti-Cancer Activity of Pelareorep-Paclitaxel Combination Therapy in HR+/HER2- Metastatic Breast Cancer at the San Antonio Breast Canc

Retrieved on: 
Donnerstag, Dezember 8, 2022
ONC, Biotechnology, Travel, PIK3CA, Global Vision, PR, Poster, Paclitaxel, Patient, Partnership, Șaeș, EP4, SD, Research, PFS, Progression-free survival, Roche, Breast cancer, Neoplasm, REO, Cancer, LINK, COVID-19, Survival, Clinical trial, Lymphatic system, AB, Safety, TSX, SAN, Pulmonary toxicity, Regulation, Pancreatic cancer, Phenotype, Medical imaging, Pharmaceutical industry, Vaccine, Pelareorep, Oncolytics Biotech

SAN DIEGO and CALGARY, AB, Dec. 8, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc.'s (NASDAQ: ONCY) (TSX: ONC) Chinese partner Adlai Nortye today announced interim results from a multicenter, single-arm bridging clinical trial to evaluate the safety, tolerability, and preliminary efficacy of pelareorep-paclitaxel combination therapy in Chinese patients with advanced/metastatic HR+/HER2- breast cancer. The data were featured in a poster presented yesterday at the San Antonio Breast Cancer Symposium (SABCS), which is being held at the Henry B. González Convention Center in San Antonio, Texas through December 10, 2022.

Key Points: 
  • 's (NASDAQ: ONCY) (TSX: ONC) Chinese partner Adlai Nortye today announced interim results from a multicenter, single-arm bridging clinical trial to evaluate the safety, tolerability, and preliminary efficacy of pelareorep-paclitaxel combination therapy in Chinese patients with advanced/metastatic HR+/HER2- breast cancer.
  • One patient achieving a PR at week 8 has maintained the PR through week 48 and remains on study.
  • The studied combination has been well tolerated, with no dose-limiting toxicities or serious adverse events (SAEs) reported to date.
  • "With no SAEs reported, the data suggests the favorable safety and potent anti-cancer activity displayed by the studied combination in North American HR+/HER2- breast cancer patients extends to the Chinese population.

2022 World Intelligent Manufacturing Conference opened in Nanjing

Retrieved on: 
Dienstag, November 29, 2022
Cloud, Xinhua Daily, Conference, Global Vision, University, Science, Intelligence, Habitat International Coalition, National Day of the Republic of China, CCTV, Video game

NANJING, China, Nov. 29, 2022 /PRNewswire/ --On November 25, the 2022 World Intelligent Manufacturing Conference opened inNanjing.

Key Points: 
  • NANJING, China, Nov. 29, 2022 /PRNewswire/ --On November 25, the 2022 World Intelligent Manufacturing Conference opened inNanjing.
  • The International Coalition of Intelligent Manufacturing and the ChinaAssociation for Science and Technology Intelligent Manufacturing Society havereleased the annual "Double Ten" scientific and technological progress at theconference for six consecutive years.
  • At the Intelligent Manufacturing Scienceand Technology Forum, academicians and experts jointly exchanged the progressof manufacturing technology, and shared solutions and application practiceswith the audience and the public.
  • Guided by "Global Vision, Chinese Strategy, Jiangsu Practice and NanjingDemonstration", the World Intelligent Manufacturing Conference brings togetherrepresentatives from international and domestic authoritative organizations,universities and institutes, and industry leading enterprises to offer adviceand suggestions for the development of intelligent manufacturing, and discusscutting-edge trends, contribute to the strength of intelligent manufacturing,continue to build a diversified and open international platform for globalintelligent manufacturing exchanges and cooperation, and successfully create ahigh-standard and high-level summit in the field of intelligent manufacturingbased in China.

Oncolytics Biotech® Announces Presentations at the Upcoming San Antonio Breast Cancer Symposium

Retrieved on: 
Montag, November 21, 2022
SAN, 2021 Essex County Council election, Cancer, TSX, Letrozole, Lymphatic system, PIK3CA, Survival, Neoplasm, Immunotherapy, Paclitaxel, Even and odd functions, Global Vision, EP4, Biotechnology, AB, Safety, Breast cancer, Progression-free survival, Roche, Travel, Phenotype, Research, Patient, COVID-19, ONC, Clinical trial, SD, PD-L1, Diagnosis, Regulation, Biomarker, Pancreatic cancer, Pharmaceutical industry, Medical imaging, Oncolytics Biotech, Pelareorep

(NASDAQ: ONCY) (TSX: ONC) today announced the publication of two abstracts for poster presentations at the upcoming San Antonio Breast Cancer Symposium (SABCS), to be held at the Henry B. Gonzlez Convention Center in San Antonio, Texas from December 6 10, 2022.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced the publication of two abstracts for poster presentations at the upcoming San Antonio Breast Cancer Symposium (SABCS), to be held at the Henry B. Gonzlez Convention Center in San Antonio, Texas from December 6 10, 2022.
  • Thebridging trial is designed to accelerate Adlai Nortye's development of pelareorep in China by allowingfuture regulatory submissions to include data from Oncolytics' North American metastatic breast cancer trials, IND-213 and BRACELET-1.
  • Described in this abstract are the results of gene expression analyses from cohorts 1 and 2 of AWARE-1, a collaborative window-of-opportunity study in patients with early-stage breast cancerthat was conducted by Oncolytics Biotech and SOLTI-Innovative Cancer Research.
  • The study combined pelareorep, without or with atezolizumab, and the standard of care therapy according to breast cancer subtype.

Oncolytics Biotech® Announces Presentations at the Upcoming San Antonio Breast Cancer Symposium

Retrieved on: 
Montag, November 21, 2022
SAN, 2021 Essex County Council election, Cancer, TSX, Letrozole, Lymphatic system, PIK3CA, Survival, Neoplasm, Immunotherapy, Paclitaxel, Even and odd functions, Global Vision, EP4, Biotechnology, AB, Safety, Breast cancer, Progression-free survival, Roche, Travel, Phenotype, Research, Patient, COVID-19, ONC, Clinical trial, SD, PD-L1, Diagnosis, Regulation, Biomarker, Pancreatic cancer, Pharmaceutical industry, Medical imaging, Oncolytics Biotech, Pelareorep

(NASDAQ: ONCY) (TSX: ONC) today announced the publication of two abstracts for poster presentations at the upcoming San Antonio Breast Cancer Symposium (SABCS), to be held at the Henry B. Gonzlez Convention Center in San Antonio, Texas from December 6 10, 2022.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced the publication of two abstracts for poster presentations at the upcoming San Antonio Breast Cancer Symposium (SABCS), to be held at the Henry B. Gonzlez Convention Center in San Antonio, Texas from December 6 10, 2022.
  • Thebridging trial is designed to accelerate Adlai Nortye's development of pelareorep in China by allowingfuture regulatory submissions to include data from Oncolytics' North American metastatic breast cancer trials, IND-213 and BRACELET-1.
  • Described in this abstract are the results of gene expression analyses from cohorts 1 and 2 of AWARE-1, a collaborative window-of-opportunity study in patients with early-stage breast cancerthat was conducted by Oncolytics Biotech and SOLTI-Innovative Cancer Research.
  • AWARE-1 was an open-label window-of-opportunity study in early-stage breast cancer.The study combined pelareorep, without or with atezolizumab, and the standard of care therapy according to breast cancer subtype.

Tishman Speyer and Project Destined Launch First Global Partnership to Introduce Students from Underserved Communities to Careers in Real Estate

Retrieved on: 
Dienstag, November 15, 2022
Equity, Rockefeller Center, Technology, Health, Taunusturm, Spring, Project Destination, Global Vision, Student, Partnership, Industry, School, Multimedia, Entrepreneurship, Business development, Inclusion, ZO, Management, Mission Rock, Studio

NEW YORK, Nov. 15, 2022 /PRNewswire/ -- Tishman Speyer today announced an agreement to serve as the first-ever Global Partner with Project Destined, a social impact platform that provides students in underserved communities with training in financial literacy, entrepreneurship and real estate. 

Key Points: 
  • Tishman Speyer's leading executives in each market will offer local students the opportunity to explore the wide range of exciting careers available to them in the real estate industry.
  • Students in each city will form teams and be tasked with evaluating actual commercial real estate transactions.
  • This inaugural "Tishman Speyer Cup" will be judged by CEO Rob Speyer and other leading executives of the firm.
  • "We are extremely proud to launch our first global partnership with Tishman Speyer," said Cedric Bobo, Project Destined Co-Founder.

Huobi Global's Major Shareholder Completes Share Sale

Retrieved on: 
Samstag, Oktober 8, 2022
23 Things They Don't Tell You About Capitalism, Global Vision, Capital, Pine River Capital Management, Acquisition, Industry, CEO, Environment, Cryptocurrency, Bank, Huobi, Limited

Upon completion of the transaction, the buyout vehicle of About Capital will control the majority stake in Huobi Global.

Key Points: 
  • Upon completion of the transaction, the buyout vehicle of About Capital will control the majority stake in Huobi Global.
  • Upon successful implementation of the initiatives, Huobi Global will be well positioned to provide first-class trading and investment services to international investors.
  • Commenting on the Huobi Global acquisition, Ted Chen, CEO of About Capital, said "We are very pleased to complete the transaction.
  • Leon Li, the founder of Huobi, said: "This transaction marks a new chapter for Huobi Global.

TECH-DRIVEN PLATFORM BRIDGETON CAPITAL RELAUNCHES AS ERITHMITIC

Retrieved on: 
Dienstag, September 27, 2022
Partner, Health, Gilt Groupe, Entrepreneurship, LLC, Nomad Health, Company, Goldman Sachs, Microsoft, Business Insider, Taunusturm, MongoDB, Venture capital, Technology, Solution, Science and technology in Asia, CRE, Global Vision, Morgan Stanley, Robotics, Spring, Nubank, Rockefeller Center, Financial services, Bank, Video game, Studio, Mission Rock, Capsule

NEW YORK, Sept. 27, 2022 /PRNewswire/ -- Private investment firm and development group Bridgeton Holdings LLC today announces the rebrand of its non-bank lending platform Bridgeton Capital to Erithmitic, in an effort to highlight the Company as a tech-enabled lender that is modernizing commercial real estate lending, ensuring process efficiencies to underwrite deals with more speed and accuracy. The Company today also announces it has closed a $6 million seed round led by AlleyCorp along with Tishman Speyer Ventures. Other investors include: Unpopular Ventures, founders of NuBank, Capsule, La Haus as well as Partners from Venture Capital firms, Ribbit Capital, and Camber Creek. Erithmitic will use the seed funding to build the next-generation commercial real estate investment platform to originate, underwrite, close and service one – five year commercial mortgage loans nationwide between $5-$150 million and across all property types.

Key Points: 
  • Other investors include: Unpopular Ventures, founders of NuBank, Capsule, La Haus as well as Partners from Venture Capital firms, Ribbit Capital, and Camber Creek.
  • TECH-DRIVEN PLATFORM BRIDGETON CAPITAL RELAUNCHES AS ERITHMITIC.
  • The Company's new brand identity as Erithmitic includes a new website and robust team of top talent with experience from Goldman Sachs, Morgan Stanley and Microsoft.
  • Bridgeton Capital was born in 2021 to originate senior secured loans for transitional properties nationwide and across property types.